A Search Service for Abbreviation / Long Form

■ Abbreviation / Long Form : anti-VEGFs / anti-vascular endothelial growth factors

[Related PubMed/MEDLINE]
Total Number of Papers: 25
[Entries Per Page]
 per page
Page Control
Page: of
Abbreviation:   anti-VEGFs  (>> Co-occurring Abbreviation)
Long Form:   anti-vascular endothelial growth factors
 Abbreviation Variation
 Long Form Variation
 Pair(Abbreviation/Long Form) Variation
No. Year Title Co-occurring Abbreviation
2022 Efficacy of an Anti-Semaphorin 3A Neutralizing Antibody in a Male Experimental Retinal Vein Occlusion Mouse Model. RVO, Sema3A, TNF
2022 Recurrent Pterygium: A Review. CAU, MMC
2022 Resistance to TKIs in EGFR-Mutated Non-Small Cell Lung Cancer: From Mechanisms to New Therapeutic Strategies. cfDNA, EGFR, NSCLC, TKIs
2022 State of the art spatial visualization of the response of neovascularisation to anti-vascular endothelial growth factor therapy. MacTel, OCTA, RNV, RNV
2022 Subthreshold Photocoagulation, Laser Endpoint Management Based on Optical Coherence Tomography Angiography in Cases of Diabetic Macular Edema Refractory to Anti-VEGF. BCVA, CMT, CVI, DCP, DME, EDI-OCT, EpM, ETDRS, FAF, FAZ, LA, logMAR, OCTA, SA, SCP, SFCT, TCA, VDs
2022 The Patient Voice in Neovascular Age-Related Macular Degeneration: Findings from a Qualitative Study. nAMD
2021 Anti-vascular endothelial growth factor therapy for age-related macular degeneration: a systematic review and network meta-analysis. nAMD, NMA, RCTs
2021 Cost-minimisation analysis of a treat-and-extend regimen with anti-VEGFs in patients with neovascular age-related macular degeneration. nAMD
2021 Dexamethasone intravitreal implant (Ozurdex) in diabetic macular edema: real-world data versus clinical trials outcomes. BCVA, CMT, DME, IOP
10  2021 Non-immediate drug hypersensitivity reactions secondary to intravitreal anti-vascular endothelial growth factors. ---
11  2021 Treatment patterns and persistence rates with anti-vascular endothelial growth factor treatment for diabetic macular oedema in the UK: A real-world study. DME
12  2020 Biomarkers for central serous chorioretinopathy. CMD, CME, CSCR, CT, CVI, OCT
13  2020 Brolucizumab: A Newly Developed Anti-VEGF Molecule for the Treatment of Neovascular Age-Related Macular Degeneration. nAMD
14  2020 Clinical-Decision Criteria to Identify Recurrent Diabetic Macular Edema Patients Suitable for Fluocinolone Acetonide Implant Therapy (ILUVIEN) and Follow-Up Considerations/Recommendations. DME, FAc
15  2020 Factors Affecting Compliance to Anti-Vascular Endothelial Growth Factor Treatment of Diabetic Macular Edema in a Cohort of Jordanian Patients. DME
16  2019 Prevention of macular edema in patients with diabetes after cataract surgery. PCME
17  2019 Treat and Extend Treatment Interval Patterns with Anti-VEGF Therapy in nAMD Patients. EMR, nAMD
18  2018 Biodegradable Microsphere-Hydrogel Ocular Drug Delivery System for Controlled and Extended Release of Bioactive Aflibercept In Vitro. DDS
19  2018 Evaluation of effect of bevacizumab on central subfield macular thickness in the injected and contralateral (untreated) eye of patients with bilateral diabetic macular oedema. CSMT, DME, SD-OCT
20  2018 Intravitreal Anti Vascular Endothelial Growth Factor Agents in The Management of Retinal Diseases: An Audit. OAP, SPSS
21  2018 [Systemic safety following intravitreal injections of anti-VEGF]. AEs
22  2016 Systematic literature review of treatments for management of complications of ischemic central retinal vein occlusion. iCRVO
23  2014 Laser photocoagulation for proliferative diabetic retinopathy. BCVA, CI, ICTRP, mRCT, RCTs, RR, WHO
24  2014 The cost-utility of aflibercept for the treatment of age-related macular degeneration compared to bevacizumab and ranibizumab and the influence of model parameters. AMD
25  2013 Branch retinal vein occlusion: treatment modalities: an update of the literature. ---